U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H32N4O4.H2O
Molecular Weight 434.5292
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ELAROFIBAN

SMILES

O.OC(=O)C[C@H](NC(=O)[C@@H]1CCCN(C1)C(=O)CCC2CCNCC2)C3=CN=CC=C3

InChI

InChIKey=VHTVZWUXMIOMAD-VOMIJIAVSA-N
InChI=1S/C22H32N4O4.H2O/c27-20(6-5-16-7-10-23-11-8-16)26-12-2-4-18(15-26)22(30)25-19(13-21(28)29)17-3-1-9-24-14-17;/h1,3,9,14,16,18-19,23H,2,4-8,10-13,15H2,(H,25,30)(H,28,29);1H2/t18-,19+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C22H32N4O4
Molecular Weight 416.5139
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/17115723 | http://adisinsight.springer.com/drugs/800010575

Elarofiban is a novel nonpeptide glycoprotein IIb/IIIa (GPIIb/IIIa) antagonist. It inhibits thrombin-induced platelet aggregation in human gel-filtered platelets and platelet aggregation in human platelet-rich plasma (PRP) in response to collagen, arachidonic acid, ADP, and SFLLRN-NH(2). Elarofiban had adequate oral pharmacokinetics in dogs and excellent oral pharmacodynamics. Elarofiban has been in phase II clinical trials for the treatment of myocardial infarction and thrombosis. However, this research has been discontinued.

Originator

Curator's Comment: the subsidiary of Johnson & Johnson

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
19.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308.
1999 Dec 16
Patents

Sample Use Guides

Oral: 3 mg/kg Intravenous: 0.03 mg/kg
Route of Administration: Other
Elarofiban inhibited platelet aggregation in human platelet-rich plasma in response to multiple agonists (collagen, ADP, TRAP-6, arachidonic acid; IC50 = 60-160 nM).
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:56:18 UTC 2023
Edited
by admin
on Wed Jul 05 23:56:18 UTC 2023
Record UNII
6Y891C0JEV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ELAROFIBAN
USAN  
USAN  
Official Name English
3-PYRIDINEPROPANOIC ACID, .BETA.-(((1-(1-OXO-3-(4-PIPERIDINYL)PROPYL)-3-PIPERIDINYL)CARBONYL)AMINO)-, (S-(R*,S*))-, MONOHYDRATE
Common Name English
RWJ-53308
Code English
(S)-β-[(R)-1-[3-(4-Piperidyl)propionyl]nipecotamido]-3-pyridinepropionic acid, monohydrate
Common Name English
ELAROFIBAN [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29750
Created by admin on Wed Jul 05 23:56:18 UTC 2023 , Edited by admin on Wed Jul 05 23:56:18 UTC 2023
Code System Code Type Description
SMS_ID
300000034131
Created by admin on Wed Jul 05 23:56:18 UTC 2023 , Edited by admin on Wed Jul 05 23:56:18 UTC 2023
PRIMARY
PUBCHEM
216231
Created by admin on Wed Jul 05 23:56:18 UTC 2023 , Edited by admin on Wed Jul 05 23:56:18 UTC 2023
PRIMARY
NCI_THESAURUS
C72753
Created by admin on Wed Jul 05 23:56:18 UTC 2023 , Edited by admin on Wed Jul 05 23:56:18 UTC 2023
PRIMARY
USAN
LL-72
Created by admin on Wed Jul 05 23:56:18 UTC 2023 , Edited by admin on Wed Jul 05 23:56:18 UTC 2023
PRIMARY
FDA UNII
6Y891C0JEV
Created by admin on Wed Jul 05 23:56:18 UTC 2023 , Edited by admin on Wed Jul 05 23:56:18 UTC 2023
PRIMARY
CAS
221005-96-5
Created by admin on Wed Jul 05 23:56:18 UTC 2023 , Edited by admin on Wed Jul 05 23:56:18 UTC 2023
PRIMARY
ChEMBL
CHEMBL87728
Created by admin on Wed Jul 05 23:56:18 UTC 2023 , Edited by admin on Wed Jul 05 23:56:18 UTC 2023
PRIMARY
EPA CompTox
DTXSID70944740
Created by admin on Wed Jul 05 23:56:18 UTC 2023 , Edited by admin on Wed Jul 05 23:56:18 UTC 2023
PRIMARY
MESH
C402922
Created by admin on Wed Jul 05 23:56:18 UTC 2023 , Edited by admin on Wed Jul 05 23:56:18 UTC 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY